Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Leukemia, Myeloid, Acute 85Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia 24Recurrence 16Lymphoma 14Myelodysplastic Syndromes 13Burkitt Lymphoma 13Congenital Abnormalities 12Lymphoma, Non-Hodgkin 10Leukemia, Monocytic, Acute 10Leukemia, Myelomonocytic, Acute 8Leukemia, Erythroblastic, Acute 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Megakaryoblastic, Acute 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Multiple Myeloma 4Hematologic Neoplasms 4Blast Crisis 4Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Biphenotypic, Acute 3Anemia, Refractory, with Excess of Blasts 3Thrombocytopenia 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2

Interventions

Filgrastim 3Carboplatin 3sodium thiosulfate 2etoposide phosphate 2Radiotherapy 2Cyclophosphamide 2Amifostine 2pegfilgrastim 1glucarpidase 1Triptorelin Pamoate 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Melphalan 1Mannitol 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Cytarabine 1Cisplatin 1Celecoxib 1Capecitabine 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Drug-Related Side Effects and Adverse Reactions × Cytarabine × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡